Pulmonary Edema Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Canada - Size and Forecast 2024-2028

Pulmonary Edema Therapeutics Market Size 2024-2028

The pulmonary edema therapeutics market size is forecast to increase by USD 365.5 million at a CAGR of 3.27% between 2023 and 2028.

• The market is experiencing significant growth due to several key factors. The high prevalence of risk factors, such as heart failure and lung diseases, is driving market demand. Additionally, the increasing use of biomarkers for disease diagnosis is facilitating early intervention and effective treatment.
• However, the market is also faced with challenges, including the adverse effects of available therapeutics and the need for safer and more effective alternatives. These factors are shaping the market landscape and influencing market growth. Overall, the market is expected to witness steady growth in the coming years, as new treatments, clinical laboratory services and diagnostic tools are developed to address these challenges and meet the evolving needs of patients.

What will be the Pulmonary Edema Therapeutics Market Size During the Forecast Period?

Request Free Sample

• The market encompasses treatments for pulmonary edema, a potentially life-threatening condition characterized by an abnormal accumulation of fluid In the lungs. This condition is often associated with heart failure, particularly In the geriatric population, and results from cardiovascular issues such as hypertensive crisis or a damaged intra-ventricular septum. Patients with pulmonary edema experience difficulty breathing due to the impaired ability of lung parenchyma to exchange oxygen and carbon dioxide.
• The market for pulmonary edema therapeutics is driven by the growing prevalence of heart failure and the increasing number of individuals In the aging population. Treatment options include medicines that help reduce fluid buildup, such as diuretics and vasodilators, as well as supplemental oxygen therapy and biomarker-based diagnostic evaluations to assess the biological state of the disease process.
• The prognosis for acute and chronic pulmonary edema varies, with timely intervention and appropriate treatment improving outcomes. Additionally, ongoing research into new therapies, such as ARIC and CHS, holds promise for advancing the field and addressing unmet needs.

How is this Pulmonary Edema Therapeutics Industry segmented and which is the largest segment?

The pulmonary edema therapeutics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type
  • Cardiogenic pulmonary edema
  • Non-cardiogenic pulmonary edema
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

By Type Insights

• The cardiogenic pulmonary edema segment is estimated to witness significant growth during the forecast period.

Pulmonary edema, a disorder characterized by fluid accumulation In the lungs, can be cardiogenic or non-cardiogenic. Cardiogenic pulmonary edema is the most prevalent form, arising from heart failure due to a diseased left ventricle's inability to eject sufficient blood. This condition increases pressure withIn the heart, leading to fluid leakage from the capillaries into the lungs' air sacs. Treatment involves medicines like diuretic drugs, vasodilators (NITROPRESS), and ACE inhibitors. Geriatric populations are particularly susceptible to heart failure and pulmonary edema due to aging-related cardiac issues and comorbidities. Cardiovascular diseases, such as hypertension, coronary artery disease, and cardiomyopathy, can also contribute to pulmonary edema.

The healthcare system offers various channels for procuring pulmonary edema therapeutics, including retail pharmacies, hospital pharmacies, and online pharmacies. Disease control and management are crucial, with collaborations, acquisitions, and mergers among therapeutic areas like cardiology, immunology, oncology, and endocrinology driving innovation. In the context of cardiac disorders, pulmonary edema can be acute or chronic, with clinical examination, imaging testing, and blood tests used for diagnosis. Supplemental oxygen, biomarkers, and diagnostic evaluations are essential components of the therapeutic process. Infrastructure investments and healthcare system advancements are vital for improving patient care and outcomes.

Get a glance at the Pulmonary Edema Therapeutics Industry report of share of various segments. Request Free Sample

The Cardiogenic pulmonary edema segment was valued at USD 1.33 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 41% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America is significantly large due to the high prevalence of risk factors leading to pulmonary edema. For instance, In the US, RSV infects and hospitalizes approximately 75,000-125,000 children annually, and sepsis, a common complication of pulmonary edema, resulted in around 270,000 deaths in 2016. Moreover, pneumococcal pneumonia, another condition linked to pulmonary edema, affects nearly 900,000 Americans each year. This market caters to various therapeutic areas, including cardiac disorders, kidney disorders, and cardiovascular diseases, such as heart failure, cardiomyopathy, and hypertension. Treatment modalities consist of medicines, supplemental oxygen, and diagnostic evaluations, including cardiac examinations, imaging tests, and blood tests.

Biomarkers play a crucial role in diagnosing and monitoring disease progression. Pulmonary edema can be cardiogenic or non-cardiogenic, with causes ranging from heart failure, hypertensive crisis, and pulmonary shunt to lung parenchymal damage and infection. Healthcare systems, retail pharmacies, hospital pharmacies, and online pharmacies distribute these therapeutics. Industry growth is driven by disease control initiatives, joint ventures, acquisitions, mergers, and collaborations.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Pulmonary Edema Therapeutics Industry?

High prevalence of risk factors is the key driver of the market.

• Pulmonary edema, a disorder characterized by the accumulation of fluid In the lungs, is a significant health concern, particularly among the geriatric population. This condition is often a complication of heart failures, including cardiogenic pulmonary edema caused by a diseased left ventricle or non-cardiogenic pulmonary edema resulting from various factors such as infections, organ failures, and trauma. Heart treatments are a primary focus in addressing pulmonary edema, with various therapeutic approaches available. These include diuretics, supplemental oxygen, and vasodilators. Disease control through joint ventures, acquisitions, and mergers among healthcare systems and pharmaceutical companies is also a driving force In the market.
• Risk factors for pulmonary edema include hypertensive crisis, intra-ventricular septum defects, and lung parenchyma damage. Infections, such as respiratory syndrome coronavirus (RSV), are a significant contributor to the disease process. Cardiovascular diseases, including carotid artery disease, cardiomyopathy, and heart valve problems, also increase the risk of developing pulmonary edema. Diagnostic evaluations, including clinical examination, imaging testing, and blood tests, are essential in diagnosing and managing pulmonary edema. Biomarkers, such as brain natriuretic peptide (BNP) and pro-B-type natriuretic peptide (pro-BNP), are valuable tools in assessing the severity of heart failure and predicting the prognosis. The market for pulmonary edema therapeutics is diverse, with various pharmaceutical products available through retail, hospital, and online pharmacies.
• Cardiac disorders and kidney disorders are therapeutic areas with significant investments in research and development. The infrastructure of healthcare systems and health care investments play a crucial role In the supply chain of these medicines. In summary, the market is driven by the high prevalence of risk factors, including infections, cardiac issues, and lifestyle habits. Diagnostic evaluations and therapeutic approaches, such as diuretics, supplemental oxygen, and vasodilators, are essential in managing this condition. The market is diverse, with various pharmaceutical products available through various channels.

What are the market trends shaping the Pulmonary Edema Therapeutics Industry?

Increasing use of biomarkers for disease diagnosis is the upcoming market trend.

• Pulmonary edema is a disorder characterized by the accumulation of fluid In the lungs, leading to difficulty breathing. This condition can be a result of heart failure, specifically cardiogenic pulmonary edema, or non-cardiogenic causes such as a hypertensive crisis or respiratory syndrome coronavirus. Diagnosis involves clinical examination, imaging testing, and blood tests to identify biomarkers indicative of heart failure, such as BNP or NT-pro-BNP. Heart failure, a leading cause of pulmonary edema, affects a significant portion of the geriatric population and those with cardiac issues like cardiomyopathy, heart valve problems, or coronary artery disease. The National Heart, Lung and Blood Institute (NHLBI) has conducted extensive research through studies like the ARIC and CHS to better understand the disease process and develop effective treatments.
• Treatment for pulmonary edema includes supplemental oxygen, medicines to reduce fluid buildup, and, in severe cases, ventilator-assisted respiration. The market for pulmonary edema therapeutics includes retail pharmacies, hospital pharmacies, and online pharmacies as distribution channels. Disease control initiatives, joint ventures, acquisitions, mergers, and collaborations among healthcare systems, pharmaceutical companies, and medical disciplines like cardiology, endocrinology, and immunology contribute to the growth of this market. The infrastructure and healthcare investments In the US have played a crucial role in providing access to advanced diagnostic tools and therapeutic interventions for pulmonary edema patients. The supply chain for pulmonary edema treatments involves wholesalers, retailers, hospitals, and clinics.
• The prognosis for pulmonary edema depends on the underlying cause and the timely administration of appropriate treatments.

What challenges does the Pulmonary Edema Therapeutics Industry face during its growth?

Adverse effects of available therapeutics is a key challenge affecting the industry growth.

• The market encompasses a range of treatments for heart conditions, particularly heart failure, which can lead to pulmonary edema. This disorder affects the geriatric population and is characterized by the accumulation of fluid In the lungs, impairing breathing and putting strain on the cardiovascular system. Cardiac issues, such as a diseased left ventricle, cardiomyopathy, heart valve problems, and hypertension, can contribute to the development of pulmonary edema. Non-cardiogenic pulmonary edema can also occur due to various reasons, including respiratory syndrome coronavirus infections, hypertensive crisis, and pulmonary shunts. Diagnostic evaluations, including clinical examination, imaging testing, and blood tests, are essential for diagnosing and monitoring the progression of pulmonary edema.
• Treatment options for pulmonary edema include medicines like diuretics, such as LASIX, which help remove excess fluid from the body. However, these drugs come with side effects, including mild adverse events like headache, fever, chills, nausea, and vomiting, and more severe side effects like dehydration, which can reduce water and electrolyte levels In the body. The National Heart, Lung and Blood Institute, along with various research studies like ARIC and CHS, have been instrumental in advancing our understanding of pulmonary edema and its treatment. Disease Control and Prevention initiatives, joint ventures, acquisitions, and mergers have played a crucial role in expanding the portfolio of pharmaceutical products available for treating pulmonary edema.
• Supplemental oxygen and ventilator-assisted respiration are also essential components of pulmonary edema treatment. The supply chain for these therapeutics involves retail pharmacies, hospital pharmacies, and online pharmacies, ensuring accessibility to patients in various healthcare settings. The prognosis for pulmonary edema depends on the underlying cause and timely intervention. Cardiovascular diseases, such as carotid artery disease, coronary artery disease, and high blood pressure, can contribute to the development of pulmonary edema and require infrastructure investments and healthcare system improvements to address effectively. In conclusion, the market is a critical area of focus for healthcare investments, with ongoing research and development efforts aimed at improving treatment options and reducing adverse effects.
• Biomarkers and diagnostic evaluations are essential tools for accurately diagnosing and monitoring pulmonary edema, while medical devices and medicines play a crucial role in managing the condition and improving patient outcomes.

Exclusive Customer Landscape

The pulmonary edema therapeutics market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the pulmonary edema therapeutics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, pulmonary edema therapeutics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• ADVANZ PHARMA
• Apotex Inc.
• Bausch Health Companies Inc.
• Baxter International Inc.
• CHIESI Farmaceutici SpA
• CMP Pharma Inc.
• Emcure Pharmaceuticals Ltd.
• Epic Pharma LLC
• Fresenius Kabi AG
• Hikma Pharmaceuticals Plc
• Johnson and Johnson Services Inc.
• Lupin Ltd.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Shanghai Fosun Pharmaceutical Group Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• Validus Pharmaceuticals LLC
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Pulmonary edema is a disorder characterized by an abnormal accumulation of fluid In the lungs' air sacs, impairing the ability to breathe effectively. This condition can be a consequence of various cardiovascular issues, including heart failure, hypertensive crisis, and cardiogenic shock. The geriatric population is particularly susceptible due to the prevalence of underlying heart conditions and age-related changes in lung function. The therapeutic market for pulmonary edema focuses on providing effective treatments to manage the symptoms and prevent further complications. The primary interventions include medicines, supplemental oxygen, and, in severe cases, mechanical ventilation. Medicines used In the treatment of pulmonary edema aim to reduce the workload on the heart and improve lung function.

These may include diuretics to eliminate excess fluid, vasodilators to improve blood flow, and ACE inhibitors to manage heart failure symptoms. Biomarkers, such as natriuretic peptides, are essential in diagnosing and monitoring the progression of heart conditions contributing to pulmonary edema. Diagnostic evaluations play a crucial role in identifying the underlying causes and determining the most appropriate treatment. Clinical examination, imaging testing, and blood tests are essential components of the diagnostic process. Imaging tests, such as chest X-rays and echocardiograms, help assess the condition of the heart and lungs, while blood tests provide valuable information on various biomarkers and other relevant laboratory values.

Devices, such as continuous positive airway pressure (CPAP) machines and mechanical ventilators, are essential in managing severe cases of pulmonary edema. These devices help maintain adequate oxygenation and ventilation, allowing the body to recover from the acute episode. The healthcare system plays a significant role In the management of pulmonary edema. Hospitals, clinics, retail pharmacies, and online pharmacies all contribute to the delivery of care. Joint ventures, acquisitions, and mergers among healthcare providers and pharmaceutical companies continue to shape the market landscape, driving innovation and improving patient access to advanced treatments. The therapeutic areas of immunology, oncology, cardiology, endocrinology, and neurology all intersect with pulmonary edema treatment.

Cardiovascular diseases, including coronary artery disease, heart valve problems, and high blood pressure, are common underlying conditions. Infection, carotid artery disease, and kidney disorders can also contribute to the development of pulmonary edema. Healthcare infrastructure and investments in research and development are essential for advancing the field of pulmonary edema therapeutics. The ongoing development of new drugs and vaccines holds great promise for improving patient outcomes and reducing the burden of this debilitating condition. In conclusion, the pulmonary edema therapeutic market encompasses a diverse range of interventions aimed at managing the symptoms and preventing complications. From medicines and supplemental oxygen to diagnostic evaluations and advanced devices, the healthcare system plays a crucial role in delivering effective care. The ongoing research and development in various therapeutic areas hold great promise for improving patient outcomes and reducing the burden of this condition.

Request Free Sample

What are the Key Data Covered in this Pulmonary Edema Therapeutics Market Research and Growth Report?

• CAGR of the Pulmonary Edema Therapeutics industry during the forecast period
• Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the pulmonary edema therapeutics market growth of industry companies

We can help! Our analysts can customize this pulmonary edema therapeutics market research report to meet your requirements.

Get in touch